# Kiora Pharmaceuticals Inc: financial statements, quarterly

KPRX · Nasdaq · CIK 1372514 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/kprx.md) · [Financials](/companies/kprx/financials.md) · [Filings](/companies/kprx/filings.md) · [Insiders](/companies/kprx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/kprx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001372514-24-000120.md) | [0.0 d](/filings/0001372514-25-000012.md) | [16.0](/filings/0001372514-25-000044.md) | [0.0](/filings/0001372514-25-000061.md) | [0.0](/filings/0001372514-25-000078.md) | [0.0 d](/filings/0001372514-26-000024.md) | [0.0](/filings/0001372514-25-000044.md) | [0.0](/filings/0001372514-25-000061.md) | [0.0](/filings/0001372514-25-000078.md) | [0.0 d](/filings/0001372514-26-000024.md) | not reported | not reported |
| Research and development | $m | [1.1](/filings/0001372514-24-000120.md) | [1.1 d](/filings/0001372514-25-000012.md) | [1.7](/filings/0001372514-25-000044.md) | [2.0](/filings/0001372514-25-000061.md) | [2.2](/filings/0001372514-25-000078.md) | [1.9 d](/filings/0001372514-26-000024.md) | [2.5](/filings/0001372514-26-000047.md) | [2.6](/filings/0001372514-26-000074.md) | [2.7](/filings/0001372514-25-000078.md) | [2.9 d](/filings/0001372514-26-000024.md) | [2.1](/filings/0001372514-26-000047.md) | [2.1](/filings/0001372514-26-000074.md) |
| Operating income | $m | [(5.9)](/filings/0001372514-24-000120.md) | [(2.1) d](/filings/0001372514-25-000012.md) | [13.2](/filings/0001372514-25-000044.md) | [(2.5)](/filings/0001372514-25-000061.md) | [(3.6)](/filings/0001372514-25-000078.md) | [(2.6) d](/filings/0001372514-26-000024.md) | [(2.3)](/filings/0001372514-26-000047.md) | [(2.4)](/filings/0001372514-26-000074.md) | [(0.8)](/filings/0001372514-25-000078.md) | [(7.3) d](/filings/0001372514-26-000024.md) | [(2.5)](/filings/0001372514-26-000047.md) | [(2.2)](/filings/0001372514-26-000074.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | [0.0](/filings/0001372514-25-000044.md) | [0.0](/filings/0001372514-25-000061.md) | [0.0](/filings/0001372514-25-000078.md) | [2.1 d](/filings/0001372514-26-000024.md) | [0.1](/filings/0001372514-26-000047.md) | [(0.1)](/filings/0001372514-26-000074.md) | [(0.6)](/filings/0001372514-25-000078.md) | [(0.6) d](/filings/0001372514-26-000024.md) | [0.0](/filings/0001372514-26-000047.md) | [0.0](/filings/0001372514-26-000074.md) |
| Net income | $m | [(5.8)](/filings/0001372514-24-000120.md) | [(2.3) d](/filings/0001372514-25-000012.md) | [13.5](/filings/0001372514-25-000044.md) | [(2.2)](/filings/0001372514-25-000061.md) | [(3.4)](/filings/0001372514-25-000078.md) | [(4.2) d](/filings/0001372514-26-000024.md) | [(2.2)](/filings/0001372514-26-000047.md) | [(2.2)](/filings/0001372514-26-000074.md) | [0.0](/filings/0001372514-25-000078.md) | [(6.5) d](/filings/0001372514-26-000024.md) | [(2.4)](/filings/0001372514-26-000047.md) | [(2.1)](/filings/0001372514-26-000074.md) |
| Diluted EPS | $ per share | [(7.30)](/filings/0001372514-24-000120.md) | not reported | [3.46](/filings/0001372514-25-000044.md) | [(0.53)](/filings/0001372514-25-000061.md) | [(0.81)](/filings/0001372514-25-000078.md) | not reported | [(0.52)](/filings/0001372514-26-000047.md) | [(0.54)](/filings/0001372514-26-000074.md) | [0.01](/filings/0001372514-25-000078.md) | not reported | [(0.58)](/filings/0001372514-26-000047.md) | [(0.34)](/filings/0001372514-26-000074.md) |
| Basic EPS | $ per share | [(7.30)](/filings/0001372514-24-000120.md) | not reported | [4.67](/filings/0001372514-25-000044.md) | [(0.53)](/filings/0001372514-25-000061.md) | [(0.81)](/filings/0001372514-25-000078.md) | not reported | [(0.52)](/filings/0001372514-26-000047.md) | [(0.54)](/filings/0001372514-26-000074.md) | [0.01](/filings/0001372514-25-000078.md) | not reported | [(0.58)](/filings/0001372514-26-000047.md) | [(0.34)](/filings/0001372514-26-000074.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [5.4](/filings/0001372514-23-000158.md) | [2.5](/filings/0001372514-25-000012.md) | [31.3](/filings/0001372514-24-000053.md) | [6.6](/filings/0001372514-24-000104.md) | [5.6](/filings/0001372514-24-000120.md) | [3.8](/filings/0001372514-26-000024.md) | [3.8](/filings/0001372514-25-000044.md) | [1.0](/filings/0001372514-25-000061.md) | [5.5](/filings/0001372514-25-000078.md) | [8.7](/filings/0001372514-26-000074.md) | [11.0](/filings/0001372514-26-000047.md) | [7.1](/filings/0001372514-26-000074.md) |
| Current assets | $m | [7.0](/filings/0001372514-23-000158.md) | [4.7](/filings/0001372514-25-000012.md) | [33.5](/filings/0001372514-24-000053.md) | [31.8](/filings/0001372514-24-000104.md) | [31.7](/filings/0001372514-24-000120.md) | [29.7](/filings/0001372514-26-000024.md) | [27.1](/filings/0001372514-25-000044.md) | [24.7](/filings/0001372514-25-000061.md) | [22.7](/filings/0001372514-25-000078.md) | [21.7](/filings/0001372514-26-000074.md) | [18.7](/filings/0001372514-26-000047.md) | [21.3](/filings/0001372514-26-000074.md) |
| Total assets | $m | [15.9](/filings/0001372514-23-000158.md) | [13.7](/filings/0001372514-25-000012.md) | [42.4](/filings/0001372514-24-000053.md) | [40.8](/filings/0001372514-24-000104.md) | [38.5](/filings/0001372514-24-000120.md) | [36.5](/filings/0001372514-26-000024.md) | [34.0](/filings/0001372514-25-000044.md) | [31.9](/filings/0001372514-25-000061.md) | [29.9](/filings/0001372514-25-000078.md) | [24.3](/filings/0001372514-26-000074.md) | [21.2](/filings/0001372514-26-000047.md) | [23.8](/filings/0001372514-26-000074.md) |
| Current liabilities | $m | [2.1](/filings/0001372514-23-000158.md) | [1.6](/filings/0001372514-25-000012.md) | [1.6](/filings/0001372514-24-000053.md) | [1.7](/filings/0001372514-24-000104.md) | [3.5](/filings/0001372514-24-000120.md) | [6.0](/filings/0001372514-26-000024.md) | [5.3](/filings/0001372514-25-000044.md) | [3.2](/filings/0001372514-25-000061.md) | [2.6](/filings/0001372514-25-000078.md) | [3.6](/filings/0001372514-26-000074.md) | [2.8](/filings/0001372514-26-000047.md) | [2.4](/filings/0001372514-26-000074.md) |
| Total liabilities | $m | [7.8](/filings/0001372514-23-000158.md) | [7.6](/filings/0001372514-25-000012.md) | [7.5](/filings/0001372514-24-000053.md) | [7.7](/filings/0001372514-24-000104.md) | [8.5](/filings/0001372514-24-000120.md) | [10.7](/filings/0001372514-26-000024.md) | [10.3](/filings/0001372514-25-000044.md) | [9.8](/filings/0001372514-25-000061.md) | [7.5](/filings/0001372514-25-000078.md) | [8.1](/filings/0001372514-26-000074.md) | [7.3](/filings/0001372514-26-000047.md) | [6.9](/filings/0001372514-26-000074.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [8.1](/filings/0001372514-24-000120.md) | [6.1](/filings/0001372514-26-000024.md) | [34.9](/filings/0001372514-25-000061.md) | [33.1](/filings/0001372514-25-000078.md) | [30.0](/filings/0001372514-25-000078.md) | [25.8](/filings/0001372514-26-000074.md) | [23.7](/filings/0001372514-26-000074.md) | [22.1](/filings/0001372514-26-000074.md) | [22.4](/filings/0001372514-25-000078.md) | [16.1](/filings/0001372514-26-000074.md) | [13.9](/filings/0001372514-26-000074.md) | [16.9](/filings/0001372514-26-000074.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(2.5) d](/filings/0001372514-24-000120.md) | [(2.6) d](/filings/0001372514-25-000012.md) | [13.6](/filings/0001372514-25-000044.md) | [(3.7) d](/filings/0001372514-25-000061.md) | [0.9 d](/filings/0001372514-25-000078.md) | [(2.3) d](/filings/0001372514-26-000024.md) | [(2.7)](/filings/0001372514-26-000047.md) | [(3.8) d](/filings/0001372514-26-000074.md) | [(1.3) d](/filings/0001372514-25-000078.md) | [(2.2) d](/filings/0001372514-26-000024.md) | [(3.2)](/filings/0001372514-26-000047.md) | [(1.9) d](/filings/0001372514-26-000074.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001372514-24-000120.md) | [0.0 d](/filings/0001372514-25-000012.md) | not reported | not reported | [0.0 d](/filings/0001372514-25-000078.md) | [(0.0) d](/filings/0001372514-26-000024.md) | [0.0](/filings/0001372514-26-000047.md) | [0.0 d](/filings/0001372514-26-000074.md) | [0.0 d](/filings/0001372514-25-000078.md) | [0.1 d](/filings/0001372514-26-000024.md) | [0.0](/filings/0001372514-26-000047.md) | [0.0 d](/filings/0001372514-26-000074.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [849](/filings/0001372514-23-000158.md) | [1,863](/filings/0001372514-24-000053.md) | [366](/filings/0001372514-24-000104.md) | [790](/filings/0001372514-24-000120.md) | [3,892](/filings/0001372514-25-000044.md) | [4,171](/filings/0001372514-25-000061.md) | [4,215](/filings/0001372514-25-000078.md) | [4,217](/filings/0001372514-26-000047.md) | [3,989](/filings/0001372514-26-000074.md) | [4,362](/filings/0001372514-25-000078.md) | [4,175](/filings/0001372514-26-000047.md) | [6,178](/filings/0001372514-26-000074.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,424,387 at 2026-08-05, from the cover of the [10-Q filed 2026-08-07](/filings/0001372514-26-000074.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.